Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.67 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.57 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.57 |
| ▸ | ADK | P55263 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADA | P00813 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-118812615-A | 7-Denitrification-2' -C-methyl adenosine phosphoramidite monomer and synthesis method thereof | 江苏合甘元生物科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-20230372370-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF COVID-19 | Orcosa Inc. (US) | 2023-11-23 | — | — | US | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| CN-114641299-A | Methods for treating SARS CoV-2 infection | 吉利德科学公司 | 2022-06-17 | — | — | CN | claimed |
| EP-2680859-B1 | COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSTICS FOR TREATMENT OF HEPATIC STEATOSIS ALONE OR IN COMBINATION WITH A HEPATITIS C VIRUS INFECTION | SCHENTAG JEROME (US) | 2022-04-27 | — | — | EP | claimed |
| CN-114273182-A | Coating and cooking utensil | 武汉苏泊尔炊具有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | claimed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| US-20040259934-A1 | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds | OLSEN DAVID B (US) | 2004-12-23 | — | — | US | claimed |
| EP-1476169-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | claimed |
| CN-1498221-A | Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase | — | 2004-05-19 | — | — | CN | claimed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | claimed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | claimed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | claimed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | ADORA2A 2823/4885PRMT5 2463/4885WDR77 1820/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20040259934-A1 | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds | SARS1, ACE, ACE2 | ADORA2A 421/4885PRMT5 1170/4885WDR77 2008/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADORA2A 416/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | ADORA2A 192/4885PRMT5 1470/4885WDR77 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.